Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

The immunosuppressive molecule programmed death-ligand 1 (PD-L1) is frequently
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …

Cancer immunotherapy is a type of treatment that harnesses the power of the immune
systems of patients to target cancer cells with better precision compared to traditional …

Immunotherapy is a new type of tumor treatment after surgery, radiotherapy and
chemotherapy, which can be used to manage and destroy tumor cells through activating or …

Cancer is the second leading cause of death worldwide. Traditional approaches, such as
surgery, chemotherapy, and radiotherapy have been the main cancer therapeutic modalities …

Herein we trace links between biochemical pathways, pathogenesis, and metabolic
diseases to set the stage for new therapeutic advances. Cellular and acellular …

Simple Summary In this study, we provide a basal and longitudinal evaluation of immune
cells in advanced non-small-cell lung cancer (NSCLC) patients undergoing PD-1 or PD-L1 …

Cancer immunotherapies have yielded promising outcomes in various malignant tumors by
blocking specific immune checkpoint molecules, such as programmed cell death 1 and …

Emerging evidence on molecular biology related to tumors, inflammation, and immunity,
highlights their architectural commonality shifting cancer treatment paradigms toward more …

Tumor immunotherapy has revolutionized the field of oncology treatments in recent years.
As one of the promising strategies of cancer immunotherapy, tumor immunogenic cell death …